|
WO2020092155A1
|
|
Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
KR20210009421A
|
|
Multispecific antibody construct
|
|
US2019010220A1
|
|
Conditionally active chimeric antigen receptors for modified t-cells
|
|
EP3565846A1
|
|
Protein therapeutics for treatment of senescent cells
|
|
SG11201901411VA
|
|
Conditionally active polypeptides and methods of generating them
|
|
CN109311987A
|
|
Anti- ROR2 antibody, antibody fragment and their immunoconjugates with and application thereof
|
|
SG11201808994YA
|
|
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
|
US2017199198A1
|
|
Diagnostics using conditionally active antibodies
|
|
CN108780094A
|
|
The diagnostic method of use condition active antibodies
|
|
MX2018005063A
|
|
Conditionally active polypeptides.
|
|
SG11201705988UA
|
|
Conditionally active biological proteins
|
|
AU2015242961A1
|
|
Novel methods of protein evolution
|
|
BR112017004131A2
|
|
method of producing a conditionally active biological protein, conditionally active biological protein, chimeric antigen receptor, and cytotoxic cell.
|
|
CA2959141A1
|
|
Conditionally active chimeric antigen receptors for modified t-cells
|
|
AU2015204268A1
|
|
Mirac Proteins
|
|
MX2016014824A
|
|
Conditionally active biological proteins.
|
|
AU2015204840A1
|
|
Proteins targeting orthologs
|
|
EP2847231A1
|
|
Multi-specific monoclonal antibodies
|
|
AU2013251482A1
|
|
Anti-CD22 antibodies
|
|
EP3470433A1
|
|
Modified antibody regions and uses thereof
|
